To the Editor We read with great interest the article by Kutner et al.1 The authors showed that discontinuing statins in patients with a limited life expectancy is safe and may lead to improved quality of life. The accompanied editorial2 states that the statin trial provides a starting point for deprescribing trials in frail patients with advanced illness.
Geijteman ECT, Tiemeier H, van Gelder T. Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness. JAMA Intern Med. 2015;175(10):1724-1725. doi:10.1001/jamainternmed.2015.3997